Condition

Non-small-cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 64 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials64

Recruiting2

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung CancerNCT06141226 · 2023-04-12

The Research Plan of Taiwan Precision MedicineNCT04849481 · 2021-06-23

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.NCT06546553 · 2024-09-06

Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsNCT06245837 · 2024-03-20

ACTIVE_NOT_RECRUITING

Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With OsimertinibNCT07559526 · 2024-03-20

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsNCT06285097 · 2024-02-08

Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNCT05900219 · 2023-09-24

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung CancerNCT05329025 · 2022-06-01

Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)NCT05815472 · 2021-09-28

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %NCT04547504 · 2020-12-22

ACTIVE_NOT_RECRUITING

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsNCT04628780 · 2020-12-16

Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 InsertionsNCT04382300 · 2020-06-30

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid TumorsNCT04489862 · 2020-05-13

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLCNCT04371796 · 2020-05-10

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesNCT04181788 · 2020-03-18

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLCNCT04133337 · 2019-11-01

Multiplex Analysis of Circulating Tumor DNANCT03301961 · 2019-04-11

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272 · 2019-03-20

ACTIVE_NOT_RECRUITING

Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer PatientsNCT02696525 · 2018-12-01

Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New BiomarkersNCT03658460 · 2018-08-22

Early Diagnosis of Small Pulmonary Nodules by Multi-omics SequencingNCT03320044 · 2017-10-18

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation AbundanceNCT03267654 · 2017-10-12

18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical StudyNCT02938546 · 2016-11-01

Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation AbundanceNCT02930954 · 2016-11-01

Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer PatientsNCT02965391 · 2016-11-01

Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective StudyNCT02907606 · 2016-09-01

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid TumorsNCT02886897 · 2016-07-01

Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung CancerNCT02577341 · 2015-08-01

Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNANCT02833467 · 2015-01-01

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor MutationNCT02095782 · 2014-03-01

A Prospective Epidemiologic Study of ALK-Positive NSCLC in ChinaNCT02042105 · 2013-11-11

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR MutationNCT01929200 · 2013-08-01

Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised StudyNCT01887795 · 2013-08-01

Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain MetastasesNCT01926171 · 2013-06-01

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)NCT01833572 · 2013-05-01

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC PatientsNCT01843647 · 2013-04-01

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung CancerNCT01836679 · 2013-04-01

Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain MetastasesNCT01763385 · 2012-11-01

Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)NCT01511081 · 2012-08-01

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With CisplatinNCT01641575 · 2012-07-01

Role of SPECT in Radiotherapy of Lung Cancer and Toxicity EvaluationNCT01745484 · 2012-06-01

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung CancerNCT01580735 · 2012-05-01

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the LungNCT01561456 · 2011-12-01

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus ErlotinibNCT01377376 · 2011-07-01

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.NCT01124864 · 2010-10-01

Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer PatientsNCT01136083 · 2010-09-01

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung CancerNCT01138163 · 2010-06-01

A Study of ARQ 197 in Combination With ErlotinibNCT01069757 · 2010-02-01

TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung CancerNCT00940069 · 2009-03-01

A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung CancerNCT00369447 · 2009-03-01

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)NCT00832819 · 2009-02-01

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung CancerNCT00749567 · 2008-07-01

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNCT00704392 · 2008-06-01

Pemetrexed Plus Bevacizumab in Non Small Cell Lung CancerNCT00741221 · 2008-06-01

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung CancerNCT00741195 · 2008-04-01

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)NCT00686322 · 2008-04-01

Pemetrexed Followed by Docetaxel or in Reverse SequenceNCT01442909 · 2008-03-01

Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)NCT00478699 · 2007-06-01

Study of XL281 in Adults With Solid TumorsNCT00451880 · 2007-02-01

Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLCNCT00442026 · 2006-12-01

Common interventions

Leading sponsors

Peking University People's Hospital 6 Hellenic Oncology Research Group 4 Pfizer 4 Betta Pharmaceuticals Co., Ltd. 3 Kyowa Kirin Co., Ltd. 3 AstraZeneca 2 Exelixis 2 Guangdong Association of Clinical Trials 2 Qilu Pharmaceutical Co., Ltd. 2 Shanghai Chest Hospital 2 Sichuan Cancer Hospital and Research Institute 2 Sun Yat-sen University 2 Taipei Veterans General Hospital, Taiwan 2 Aalborg University Hospital 1 Agenus Inc. 1

Trial status mix

COMPLETED28

UNKNOWN19

TERMINATED11

ACTIVE_NOT_RECRUITING3

RECRUITING2

WITHDRAWN1

Phase mix

PHASE228

PHASE114

PHASE37

NA4

PHASE43

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.